📬 Breast Cancer Intelligence Digest — Week 2026-W41

evERA is published in NEJM with giredestrant plus everolimus doubling PFS in ESR1-mutated HR+/HER2- advanced breast cancer, 10-year CHN HYPOPMRT data support 3-week postmastectomy radiotherapy, and real-world series define post-T-DXd and post-CDK4/6 sequencing.

⚡ TL;DR

📄 Publications

Giredestrant plus Everolimus in Advanced Breast Cancer. — Phase 3 open-label randomized trial in ER-positive, HER2-negative locally advanced or metastatic breast cancer progressing after a CDK4/6 inhibitor plus endocrine therapy; 373 patients randomized, 183 to giredestrant-everolimus and 190 to standard therapy-everolimus
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial. — 820 patients enrolled and randomly assigned (414 conventional, 406 hypofractionated), with 810 analysed (409 vs 401)

🐦 Twitter / 🦋 Bluesky

evERA published in NEJM: giredestrant plus everolimus doubles PFS after CDK4/6 inhibition, but the benefit sits in ESR1-mutated disease — In the overall population median PFS was 8.8 vs 5.5 months (HR 0.56; 95% CI 0.44-0.71; P<0.001)
Blood-derived neoantigen identification could remove the tumor biopsy requirement for personalized cancer vaccines — Personalized neoantigen vaccines have already been shown to improve outcomes in refractory malignant melanoma and in pilot studies including triple negative breast cancer, but they require a tumor biopsy to identify the antigens
A JCI review argues breast cancer immunotherapy selection should measure the patient's immune status, not just the tumor — The review covers how immunotherapy should be optimally applied for breast cancer and emphasizes the patient, not just the tumor, immune status
Gut microbiome patterns track with early-onset breast and colon cancer, treatment toxicity and survival — The gut microbiome patterns with early-onset breast and colon cancer, adverse effect response to treatments, and prediction for survival

Full details below ↓

📄 What's Being Published

Manuscripts:

Giredestrant plus Everolimus in Advanced Breast Cancer. — Mayer Erica L et al., N Engl J Med

In this phase 3 open-label trial, 373 patients with ER-positive, HER2-negative advanced breast cancer progressing after a CDK4/6 inhibitor plus endocrine therapy were randomized to giredestrant-everolimus (183) or standard therapy-everolimus (190). Among 207 patients with ESR1-mutated tumors, median progression-free survival was 10.0 vs 5.5 months (HR 0.38; 95% CI, 0.27 to 0.54; P<0.001). In the overall population it was 8.8 vs 5.5 months (HR 0.56; 95% CI, 0.44 to 0.71; P<0.001). Adverse events occurred in 98.9% vs 96.8% of patients, most commonly stomatitis (47.3% vs 48.9%), diarrhea (26.9% vs 22.6%), and anemia (23.6% vs 21.0%).

Clinical bottom line: After progression on a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, the all-oral giredestrant-everolimus doublet belongs primarily in ESR1-mutated disease, where PFS roughly doubles, not in all comers.

Read full article →

🔗 Also discussed on social media →

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial. — Sun Guang-Yi et al., Lancet Oncol

The trial randomized 820 patients to 50 Gy in 25 fractions over 5 weeks or 43.5 Gy in 15 fractions over 3 weeks to the chest wall and supraclavicular region; 810 were analysed. Median follow-up was 11.5 years, median age was 49 years, and 761 (94%) had stage III disease. At 10 years, cumulative locoregional recurrence was 10.3% with conventional vs 12.0% with hypofractionated radiotherapy (HR 1.19, 95% CI 0.79-1.82), with no grade 4-5 events, brachial plexopathy, serious adverse events, or treatment-related deaths.

Clinical bottom line: Three-week hypofractionated postmastectomy radiotherapy with regional nodal irradiation holds up at 10 years in high-risk, mostly stage III disease, and conventional 5-week fractionation no longer needs to be the default.

Read full article →

Palliative Care for Advanced Cancer in Medicare Advantage and Physician Networks. — Hu Xin et al., JAMA Netw Open

This retrospective SEER-Medicare cohort included 135 402 beneficiaries aged 66 or older with distant-stage breast, colorectal, lung, pancreatic, or prostate cancer; 32.3% were in Medicare Advantage and 67.7% in traditional Medicare. Medicare Advantage beneficiaries had higher 6-month cumulative incidence of palliative care (13.3% vs 9.3%; AHR 1.39, 95% CI 1.35-1.44; P<.001), but after matching on treating oncologist there was no difference (AHR 1.05, 95% CI 0.98-1.12; P=.19). Medicare Advantage beneficiaries had lower systemic therapy receipt (-5.38 percentage points) and higher hospice enrollment (3.42 pp), differences that persisted after matching.

Clinical bottom line: Higher palliative care use in Medicare Advantage is largely explained by which oncologists patients see, whereas lower systemic therapy and higher hospice use persist regardless of physician network — a coverage-level difference oncologists should factor into advanced breast cancer care planning.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

evERA published in NEJM: giredestrant plus everolimus doubles PFS after CDK4/6 inhibition, but the benefit sits in ESR1-mutated disease

With evERA now in print, clinicians focused on where the PFS gain sits: it was concentrated in ESR1-mutated tumors, while in tumors without a detectable ESR1 mutation PFS was nearly identical between arms. Overall survival remains immature but shows a favorable numerical trend (ITT HR 0.69; ESR1-mutated HR 0.62), and some questioned the comparator given that 31% of patients had PIK3CA mutations, asking whether alpelisib + fulvestrant would better clarify the regimen's role. In a clinician poll on second-line choice for an ESR1-mutant patient, imlunestrant + abemaciclib (43.1%) edged out giredestrant + everolimus (32.5%). The open question is which doublet to choose after CDK4/6 inhibitor progression with an emergent ESR1 mutation, and whether either has a place in ESR1 wild-type disease.

Key numbers: ESR1-mut PFS 10.0 vs 5.5 mo, HR 0.38 · Overall PFS 8.8 vs 5.5 mo, HR 0.56 · ESR1 wild-type PFS 5.7 vs 5.5 mo, HR 0.84 · ORR 23.8% vs 11.7% · ESR1-mut ORR 26.6% vs 13.8%

Discussed by: @PTarantinoMD, @OncBrothers, @stolaney1, @stolaney1, @jhaveri_komal, @OncBrothers, @dr_yakupergun, @dr_yakupergun, @SuyogCancer, @Dr_ElvinaA, @Dr_Oncologista, @ozdogan_md

→ View representative tweet

Sources cited: NEJM · Giredestrant plus Everolimus in Advanced Breast Cancer. (N Engl J Med) · OncoDaily

Blood-derived neoantigen identification could remove the tumor biopsy requirement for personalized cancer vaccines

Personalized neoantigen vaccines have improved outcomes in refractory malignant melanoma and in pilot studies including triple negative breast cancer, but require a tumor biopsy to identify antigens; a new study shows these can be obtained from a blood sample. Separately, serial cfDNA testing in more than 12,000 patients with metastatic breast cancer detected newly emerging resistance mutations before clinical progression, and a liquid biopsy tumor board debated whether ctDNA can move from predicting recurrence to guiding treatment in early breast cancer. The debate is which decision blood-only profiling should drive first: vaccine manufacture, or a change of systemic therapy before radiographic progression.

Discussed by: @EricTopol, @YaleCancer, @RobertoBoreaMD

→ View representative tweet

Sources cited: Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery (Cancer Discovery, 2026)

A JCI review argues breast cancer immunotherapy selection should measure the patient's immune status, not just the tumor

A review in the Journal of Clinical Investigation on optimal use of immunotherapy in breast cancer emphasizes the patient's immune status, not just the tumor's. A multi-cohort study in advanced triple-negative breast cancer identified a transcriptomic signature that stratifies progression-free survival after chemo-immunotherapy: immune-enriched tumors with organized lymphoid architecture had better outcomes, while fibrotic and angiogenic microenvironments, often with PI3K alterations, had poorer outcomes. The question is whether selection in advanced TNBC should move beyond PD-L1 to microenvironment signatures and host immune status, and who would pay for that testing today.

Discussed by: @EricTopol, @weoncologists, @RobertoBoreaMD

→ View representative tweet

Sources cited: Cell Press

Gut microbiome patterns track with early-onset breast and colon cancer, treatment toxicity and survival

Gut microbiome patterns were linked to early-onset breast and colon cancer, adverse effects of treatment, and survival prediction. The Lancet Oncology's October issue put cancer and the microbiome on its cover. The open question is whether microbiome profiling is close enough to prognostic or toxicity-predictive use in early-onset breast cancer to justify collecting stool samples on trial, or whether it remains descriptive.

Discussed by: @EricTopol, @thelancetoncol.bsky.social

→ View representative tweet

Sources cited: Cell Press

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @OncoAlert: What does 6 years of follow-up tell us about 1 year of adjuvant olaparib? The OlympiA trial continues to show meaningful improvements in disease-free and overall survival in high-risk, 🧬HER2-negative early #BreastCancer

In this #WeekinOncology by OncoAlert, we have our colleague Dr. Gaia Griguolo 🇮🇹 discussing the latest update of OlympiA

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial

Link to Article
https://t.co/JPDHcD3m8L

The OlympiA trial shows that one year of adjuvant olaparib provides sustained benefits in patients with high-risk, HER2-negative early breast cancer and germline BRCA1/2 pathogenic variants.
➡️At 6.1 years, olaparib improved invasive disease-free, distant disease-free, and overall survival, with a 4.4% absolute six-year OS benefit.
➡️Benefits were consistent across subgroups. Toxicity remained acceptable, with no increased risk of MDS or AML, supporting continued adjuvant use.

@LoiblSibylle, @MichaelGnant, @drkellyphillips, @ZoppoliGabriele

@hoperugo, @matteolambe, @ErikaHamilton9, @DrSGraff, @aftimosp, @BianchiniGP, @raalbany, @jamecancerdoc, @Icro_Meattini, @stolaney1, @maryam_lustberg, @LoiSher, @stage4kelly, @JaniceTNBCmets, @TanjaSpanic, @christeeny513, @stage4kelly, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @UOzkerim, @DrVilmaPBarcia, @nataliagandur

🔖 1 ❤️ 16 🔁 10 👁 1,909

📬 Breast Cancer Intelligence Digest — Week 2026-W41

⚡ TL;DR

📄 What's Being Published

🗣️ What People Were Discussing This Week

evERA published in NEJM: giredestrant plus everolimus doubles PFS after CDK4/6 inhibition, but the benefit sits in ESR1-mutated disease

Blood-derived neoantigen identification could remove the tumor biopsy requirement for personalized cancer vaccines

A JCI review argues breast cancer immunotherapy selection should measure the patient's immune status, not just the tumor

Gut microbiome patterns track with early-onset breast and colon cancer, treatment toxicity and survival

🔥 Top Ranked Tweets

🧪 Newly Recruiting Trials